TRANSGENE
LIVE

Serial Number

79429882

Owner

TRANSGENE

Attorney

Pina Campagna

Filing Date

Jul 10, 2025

Add to watchlist:

No watchlists yet
View on USPTO

TRANSGENE Trademark

Serial Number: 79429882

TRANSGENE is a trademark filed by TRANSGENE on July 10, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

TRANSGENE (3 trademarks)

Parc d'Innovation,

Entity Type: 33

Trademark Details

Filing Date

July 10, 2025

Registration Date

Not Registered

Goods & Services

Medicines for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; anti-cancer medicines; cancer treatment compounds in the nature of pharmaceutical preparations; pharmaceutical preparations and substances for cancer treatment and prevention; immunotherapeutic pharmaceutical preparations for the prevention and the treatment of cancer; immunotherapeutic pharmaceutical preparations for the prevention and the treatment of bacterial infections; personalized immunotherapeutic pharmaceutical preparations for the prevention and the treatment of cancer, bacterial infections; pharmaceutical preparations to stimulate and modulate the immune system; pharmaceutical preparations comprising oncolytic viruses for the prevention and the treatment of cancer; medicinal preparations and pharmaceutical preparations for the treatment of infectious and genetic diseases; pharmaceutical preparations for use in chemotherapy for cancer treatment; chemotherapeutic agents being pharmaceutical preparations for the treatment of cancer and viral infections and for the prevention of cancer recurrence; Pharmaceutical substances and preparations used in oncology for the treatment of cancer and viral infections and for the prevention of cancer recurrence; vaccines; cancer vaccines; therapeutic vaccines in oncology or genetics; viral vaccines; tumor antigens being pharmaceutical preparations for the treatment of cancer and viral infections and for the prevention of cancer recurrence; viral antigens being pharmaceutical preparations for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; vaccine adjuvants for medical use; Chemicals and biochemicals being medical preparations for medical and clinical use for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; agents and reagents for medical or clinical use being pharmaceutical preparations for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; chemical or biochemical test kits in the nature of medical diagnostic assays for testing body samples; reagents for medical and clinical use comprising preparations, agents and reagents in the nature of pharmaceutical preparations for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; stem cells for medical use; clinical medical reagents; cytostatic medicines for medical use for the prevention and the treatment of cancer and viral infections and for the prevention of cancer recurrence; reagents for genetic testing of cancer tumors in medicine; preparations for detecting genetic predispositions of cancers for medical use

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 23, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 23, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 23, 2026 TROA
REFUSAL PROCESSED BY IB
Feb 12, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 23, 2026 RFCS
REFUSAL PROCESSED BY MPU
Jan 23, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 20, 2025 RFCR
NON-FINAL ACTION WRITTEN
Dec 19, 2025 CNRT
ASSIGNED TO EXAMINER
Nov 28, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 29, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 29, 2025 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Aug 29, 2025 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Aug 7, 2025 SDRC